المؤلفون: S. Miklishanskaya V., L. Solomasova V., A. Orlovsky A., S. Nasonova N., N. Mazur A., С. Миклишанская В., Л. Соломасова В., А. Орловский А., С. Насонова Н., Н. Мазур А.

المساهمون: The study was performed with the support of the National Medical Research Center of Cardiology., Исследование проведено при поддержке Национального медицинского исследовательского центра кардиологии.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 17, No 6 (2021); 867-872 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 6 (2021); 867-872 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: abdominal obesity, bioimpedance analysis, visceral, epicardial adipose tissue, абдоминальное ожирение, биоимпедансный анализ, висцеральная жировая ткань, триглицериды, холестерин липопротеинов высокой плотности

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2632/2265; Powell-Wiley Т, Poirier P, Burke L, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-1010. DOI:10.1161/CIR.0000000000000973.; Neeland IJ, Poirier P, Després JP. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation. 2018;137(13):1391-406. DOI:10.1161/CIR-CULATIONAHA.117.029617.; Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715-25. DOI:10.1016/S2213-8587(19)30084-1.; Omura-Ohata Y, Son C, Makino H, et. al. Efficacy of visceral fat estimation by dual bioelectrical impedance analysis in detecting cardiovascular risk factors in patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):137. DOI:10.1186/s12933-019-0941-y.; Окороков П.Л., Васюкова О.В., Воронцов А.В. Методы оценки количества и распределения жировой ткани в организме и их клиническое значение. Проблемы Эндокринологии. 2014;60(3):53-8. DOI:10.14341/probl201460353-58.; Body composition analyzer/body fat analyzer and calorie tracker. Section 6.1 Stayhealthy BC1 and Stayhealthy/Fitness Expert BC2, Body composition analyzer 510K submission [cited 2020 Jun 20]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf5/K052522.pdf.; Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J. 2010;31(6):737-46. DOI:10.1093/eurheartj/ehp487.; Jung CH, Lee WJ, Song K. Metabolically healthy obesity: a friend or foe? Korean J Intern Med. 2017;32(4):611-21. DOI:10.3904/kjim.2016.259.; Dhana K, Koolhaas CM, van Rossum E, et al. Metabolically Healthy Obesity and the Risk of Cardiovascular Disease in the Elderly Population. PLoS One. 2016;11(4):e0154273. DOI:10.1371/journal.pone.0154273.; Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5. DOI:10.1161/CIRCULATIONAHA.109.192644.; Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract. 2017;29(S1):S3-S14. DOI:10.1002/2327-6924.12510.; Ozhan H, Alemdar R, Caglar O, et al. MELEN Investigators. Performance of bioelectrical impedance analysis in the diagnosis of metabolic syndrome. J Investig Med. 2012;60(3):587-91. DOI:10.2310/JIM.0b013e318244e2d9.; Rodríguez AS, Soidán JG, Gómez JA, et al. Metabolic syndrome and visceral fat in women with cardiovascular risk factor. Nutr Hosp. 2017;34(4):863-8. DOI:10.20960/nh.1085.; National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. DOI:10.1161/circ.106.25.3143.; Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52. DOI:10.1161/CIRCULATIONAHA.105.169404.; Iacobellis G, Assael F, Ribaudo MC, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res. 2003;11(2):304-10. DOI:10.1038/oby.2003.45.; Oliverosa E, Somersa VK, Sochor O, et al. The Concept of Normal Weight Obesity. Prog Cardiovasc Dis. 2014;56(4):4260-33. DOI:10.1016/j.pcad.2013.10.003.; Tchernof A, Després JP. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev. 2013;93(1):359-404. DOI:10.1152/physrev.00033.2011.; Миклишанская С.В., Золозова Е.А., Сафиуллина А.А., Мазур Н.А. Висцеральное ожирение у больных с различными индексами массы тела. Лечащий Врач. 2020;(8):66-70. DOI:10.26295/OS.2020.19.39.011.; Миклишанская С.В., Саидова М.А., Орловский А.А., Сычев А.В., и др. Различия в накоплении висцеральной и эпикардиальной жировой ткани у больных с ишемической болезнью сердца и без нее. Русский Медицинский Журнал. 2021;(2):13-7.; Миклишанская С.В., Золозова Е.А., Орловский А.А., и др. Обоснование необходимости создания новой классификации ожирения. Лечащий Врач. 2021;(7):58-62. DOI:10.51793/OS.2021.24.7.011.; https://www.rpcardio.com/jour/article/view/2632

الاتاحة: https://www.rpcardio.com/jour/article/view/2632
https://doi.org/10.20996/1819-6446-2021-12-17

المؤلفون: S. Miklishanskaya V., L. Solomasova V., M. Mazur A., С. Миклишанская В., Л. Соломасова В., Н. Мазур А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 16, No 1 (2020); 108-117 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 1 (2020); 108-117 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: concentric remodeling, hypertrophy, systolic and diastolic left ventricle functions, lipotoxicity, bariatric surgery, концентрическое ремоделирование, гипертрофия, систолическая и диастолическая функции левого желудочка, липотоксичность, бариатрическая хирургия

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2130/1921; Obesity and overweight. World health organization. Fact sheet; updated 2018. [cited by Jun 01, 2019]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.; Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации, 2017) [цитировано 01.07.2019. Доступно на: https://scardio.ru/content/Guidelines/project/Ozhirenie_klin_rek_proekt.pdf].; Драпкина О.М., Дуболазова Ю.В., Бойцов С.А. Борьба с ожирением: «золотой стандарт» и новые горизонты. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):450-8. DOI:10.20996/1819-64462016-12-4-450-458.; Жернакова Ю.В., Железнова Е.А., Чазова И.Е., и др. Распространенность абдоминального ожирения в субъектах Российской Федерации и его связь с социально-экономическим статусом, результаты эпидемиологического исследования ЭССE-РФ. Терапевтический Архив. 2018;90(10):14-22. DOI:10.26442/terarkh201890104-22.; National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89(3):1333-445. DOI:10.1161/01.cir.89.3.1333.; Pyörälä K., De Backer G., Graham I., et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 1994;110:121-61. DOI:10.1016/0021-9150(94)90200-3.; Abel E.D., Litwin S.E., Sweeney G. Cardiac Remodeling in Obesity. Physiol Rev. 2008; 88: 389-419. DOI:10.1152/physrev.00017.2007.; Ashrafian H., Athanasiou T., le Roux C.W. Heart remodelling and obesity: the complexities and variation of cardiac geometry. Heart. 2011;97:171e172. DOI:10.1136/hrt.2010.207092.; Дедов И. И., Александров А.А., Кухаренко С.С. Сердце и ожирение. Ожирение и Метаболизм. 2006;1:14-20.; Sons H.U., Hoffmann V. Epicardial fat cell size, fat distribution and fat infiltration of the right and left ventricle of the heart. Anat Anz. 1986;161:355-73. PMID: 3729005.; Selthofer-Relatić K., Belovari T., Bijelić N., et al. Presence of Intramyocardial Fat Tissue in the Right Atrium and Right Ventricle Postmortem Human Analysis. Acta Clin Croat. 2018;57:122-9. DOI:10.20471/acc.2018.57.01.15.; McGavock J.M., Victor R.G., Unger R.H., Szczepaniak L.S. Adiposity of the heart, revisited. Ann Intern Med. 2006; 144:517-24. DOI:10.7326/0003-4819-144-7-200604040-00011.; Sharma S., Adrogue J.V., Golfman L., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692-700. DOI:10.1096/fj.04-2263com.; Szczepaniak L.S., Dobbins R.L., Metzger G.J., et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49:417-23. DOI:10.1002/mrm.10372.; Jarna C., Hannukainen J.C., Lautamäki R., et al. Reversibility of myocardial metabolism and remodelling in morbidly obese patients 6 months after bariatric surgery. Diabetes Obes Metab. 2018; 20(4): 963-73. DOI:10.1111/dom.13183.; Andersson J., Mellberg C., Otten J., et.al. Left ventricular remodelling changes without concomitant loss of myocardial fat after long-term dietary intervention. Int J Cardiol. 2016;216:92-6. DOI:10.1016/j.ijcard.2016.04.050.; Kasper E.K., Hruban R.H., Baughman K.L. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70:921-4. DOI:10.1016/00029149(92)90739-L.; Quilliot D., Alla F., Bohme P., et al. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes. 2005;29:1321-8. DOI:10.1038/sj.ijo.0803022;5.; Spinale F.G., Janicki J.S., Zile M.R. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013;112:195-208. DOI:10.1161/CIRCRESAHA.112.266882.; Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87:1285-342. DOI:10.1152/physrev.00012.2007.; Dadson K., Turdi S., Boo S., et al. Temporal and Molecular Analyses of Cardiac Extracellular Matrix Remodeling following Pressure Overload in Adiponectin Deficient Mice. PLoS ONE. 2015;10(4):e0121049. DOI:10.1371/journal.pone.0121049.; Madani S., De Girolamo S., Munoz D.M., et al. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res. 2006;69:716-25. DOI:10.1016/j.cardiores.2005.11.022.; Rajapurohitam V., Javadov S., Purdham D.M., et al. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1. J Mol Cell Cardiol. 2006;41:26574. DOI:10.1016/j.yjmcc.2006.05.001.; Xu F.P., Chen M.S., Wang Y.Z., et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation. 2004;110:1269-75. DOI:10.1161/01.CIR.0000140766.52771.6D.; Rajapurohitam V., Gan X.T., Kirshenbaum L.A., Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003;93:277-9. DOI:10.1161/01.RES.0000089255.37804.72.; Rider O.J., Lewis A.J.M., Neubauer S. Structural and Metabolic Effects of Obesity on the Myocardium and the Aorta. Obes Facts. 2014;7:329-38. DOI:10.1159/000368429.; Sletten A.C., Peterson L.R., Schaffer J.E. Manifestations and mechanisms of myocardial lipotoxicity in obesity. J Intern Med. 2018;284: 478-91. DOI:10.1111/joim.12728.; Rider O.J., Lewandowski A., Nethononda N., et al. Gender-specific differences in left ventricular remodelling in obesity: insights from cardiovascular magnetic resonance imaging. Eur Heart J. 2013;34:292-9. DOI:10.1093/eurheartj/ehs341.; Corden B., Marvao A., Dawes T., et al. Relationship between body composition and left ventricular geometry using three dimensional cardiovascular magnetic Resonance. Journal of Cardiovascular Magnetic Resonance. 2016;18:32-40. DOI:10.1186/s12968-016-0251-4.; Cummings P.M., Le B.H., Lopes M.B. Postmortem findings in morbidly obese individuals dying after gastric bypass procedures. Hum Pathol. 2007;38:593-7. DOI:10.1016/j.humpath.2006.09.021.; House A.A., Walley V.M. Right heart failure due to ventricular adiposity: “adipositas cordis” an old diagnosis revisited. Can J Cardiol. 1996;12:485-9. PMID: 8640594.; Kortelainen M.L. Myocardial infarction and coronary pathology in severely obese people examined at autopsy. Int J Obes Relat Metab Disord. 2002;26:73-9. DOI:10.1038/sj.ijo.0801852.; Roberts W.C., Won V.S., Vasudevan A., et al. Frequency of Massive Cardiac Adiposity (Floating Heart) at Necropsy and Comparison of Clinical and Morphologic Variables with Cases with Nonmassive Cardiac Adiposity at a Single Texas Hospital, 2013 to 2014. Am J Cardiol. 2016;117:1006-13. DOI:10.1016/j.amjcard.2015.12.039.; Nalliah C.J., Sanders P., Kottkamp H., Kalman J.M. The role of obesity in atrial fibrillation. Eur Heart J. 2016;37:1565-72. DOI:10.1093/eurheartj/ehv486.; Ebong I.A., Goff D.C., Rodriguez C.J., et al. Mechanisms of Heart Failure in Obesity. Obes Res ClinPract. 2014;8:e540-e548. DOI:10.1016/j.orcp.2013.12.005.; Selthofer-Relatic K. Cardiac visceral adiposity and right ventricle apex remodelling Locus minoris resistentiae. Medical Hypotheses. 2014;82:401-4. DOI:10.1016/j.mehy.2013.12.001.; Гриценко О.В., Чумакова Г.А., Шевляков И.В., Трубина Е.В. Механизмы развития сердечной недостаточности при ожирении. Российский Кардиологический Журнал. 2018;23(5):81-6. DOI:10.15829/1560-4071-20185-81-86.; De la Maza M.P., Estevez A., Bunout D., et al. Ventricular mass in hypertensive and normotensive obese subjects. Int J Obes Relat Metab Disord. 1994;18:193-7. PMID:8044192.; Alpert M.A., Lambert C.R., Terry B.E., et al. Interrelationship of left ventricular mass, systolic function and diastolic filling in normotensive morbidly obese patients. Int J Obes Relat Metab Disord. 1995;19:550-7. PMID:7489025.; Otto M.E., Belohlavek M., Khandheria B., et al. Comparison of right and left ventricular function in obese and nonobese men. Am J Cardiol. 2004;93:1569-72. DOI:10.1016/j.amjcard.2004.02.073.; Morricone L., Malavazos A.E., Coman C., et al. Echocardiographic abnormalities in normotensive obese patients: relationship with visceral fat. Obes Res. 2002;10:489-98. DOI:10.1038/oby.2002.67.; Iacobellis G., Ribaudo M.C., Leto G., et al. Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity. Obes Res. 2002;10:767-73. DOI:10.1038/oby.2002.104.; Pascual M., Pascual D.A., Soria F., et al. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart. 2003;89:1152-6. DOI:10.1136/heart.89.10.1152.; Alexander J.K. The cardiomyopathy of obesity. Prog Cardiovasc Dis. 1985;27:325-34. DOI:10.1016/S0033-0620(85)80002-5.; Glenn D.J., Wang F., Nishimoto M., et al. A Murine Model of Isolated Cardiac Steatosis Leads to Cardiomyopathy. Hypertension. 2011;57:216-22. DOI:10.1161/HYPERTENSIONAHA.110.160655;13.; Wong C.Y., O’Moore-Sullivan T., Leano R., et al. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004;110:3081-7. DOI:10.1161/01.CIR.0000147184.13872.0F.; Chinali M., de Simone G., Roman M.J., et al. Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol. 2006;47:2267-73. DOI:10.1016/j.jacc.2006.03.004.; Alpert M.A., Lambert C.R., Panayiotou H., et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol. 1995;76:1194-7. DOI:10.1016/S0002-9149(99)80338-5.; Khan M.F., Movahed M.R. Obesity cardiomyopathy and systolic function: Obesity is not independently associated with dilated cardiomyopathy. Heart Failure Reviews. 2013;18:207-17. DOI:10.1007/s10741-012-9320-4.; Peterson L.R., Waggoner A.D., Schechtman K.B., et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol. 2004;43:1399-404. DOI:10.1016/j.jacc.2003.10.062.; Kaltman A.J., Goldring R.M. Role of circulatory congestion in the cardiorespiratory failure of obesity. Am J Med. 1976;60:645-53. PMID:1020753.; Her C., Cerabona T., Bairamian M., McGoldrick K.E. Right ventricular systolic function is not depressed in morbid obesity. Obes Surg. 2006;16:1287-93. DOI:10.1381/096089206778663887.; Feuvray D., Darmellah A. Diabetes-related metabolic perturbations in cardiac myocyte. Diabetes Metab. 2008;34(Suppl 1):S3e9. DOI:10.1016/S1262-3636(08)70096-X.; Utz W., Engeli S., Haufe S., et al. Myocardial steatosis, cardiac remodelling and fitness in insulin-sensitive and insulin-resistant obese women. Heart 2011;97:1585e1589. DOI:10.1136/hrt.2011.2244511585.; McGavock J.M., Lingvay I., Zib I., et al. Cardiac steatosis in diabetes mellitus. Circulation. 2007;116:1170-5. DOI:10.1161/CIRCULATIONAHA.106.64561.; Pellegrinelli V., Carobbio S., Vidal-Puig A. Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia. 2016;59:1075-88. DOI:10.1007/s00125-0163933-4.; Pellegrinelli V., Heuvingh J., du Roure O., et al. Human adipocyte function is impacted by mechanical cues. J Pathol. 2014; 233:183-95. DOI:10.1002/path.4347.; Rayner J., Banerjee R., Holloway C.J. The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity. International Journal of Obesity. 2018;426:441-7. DOI:10.1038/ijo.2017.239.; Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology. 2004;25:4-7. DOI:10.1016/j.it.2003.10.013.; Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. Journal of Clinical Investigation. 2005;115:1111-9. DOI:10.1172/JCI25102.; Kraegen E.W., Cooney G.J., Ye J.M., et al. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity. Experimental and Clinical Endocrinology and Diabetes. 2001;109(Suppl 2):S189-201. DOI:10.1055/s-2001-18581.; Lelliott C., Vidal-Puif A.J. Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. International Journal of Obesity and Related Metabolic Disorders. 2004;28(Suppl 4): S228. DOI:10.1038/sj.ijo.0802854.; McGarry J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002;51:7-18. DOI:10.2337/diabetes.51.1.7.; Unger R.H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003;144:5159-65. DOI:10.1210/en.2003-0870.; Rayner J., Banerjee R., Holloway C.J. The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity. International Journal of Obesity. 2018;42:441-7. DOI:10.1038/ijo.2017.239.; Rider O.J., Francis J.M., Ali M.K., et al. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. J Am Coll Cardiol. 2009;54:718-26. DOI:10.1016/j.jacc.2009.02.086.; Leichman J.G., Aguilar D., King T.M., et al. Improvements in systemic metabolism, anthropometrics, and left ventricular geometry 3 months after bariatric surgery. Surg Obes Relat Dis. 2006;2:592-9. DOI:10.1016/j.soard.2006.09.005.; Varli M., Turhan S., Aras S., et al. Effects of weight loss on ventricular systolic and diastolic functions and left ventricular mass assessed by tissue doppler imaging in obese geriatric women: preliminary report. Aging Clin Exp Res. 2010;22:206-11. DOI:10.1007/bf03324798.; de las Fuentes L., Waggoner A.D., Mohammed B.S., et al. Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. J Am Coll Cardiol. 2009;54:237681. DOI:10.1016/j.jacc.2009.07.054.; Kosmala W., O'Moore-Sullivan T., Plaksej R., et al. Improvement of left ventricular function by lifestyle intervention in obesity: Contributions of weight loss and reduced insulin resistance. Diabetologia. 2009;52:2306-16. DOI:10.1007/s00125-009-1507-4.; Shah R.V., Murthy V.L., Abbasi S.A. et al. Weight loss and progressive left ventricular remodelling: The Multi-Ethnic Study of Atherosclerosis (MESA) Eur J Prev Cardiol. 2015;22:1408-18. DOI:10.1177/2047487314541731.; Kaier T.E., Morgan D., Grapsa J., et al. Ventricular remodelling post-bariatric surgery: is the type of surgery relevant? A prospective study with 3D speckle tracking. Eur Heart J Cardiovasc Imaging. 2014 Nov;15(11):1256-62. DOI:10.1093/ehjci/jeu116.; https://www.rpcardio.com/jour/article/view/2130

الاتاحة: https://www.rpcardio.com/jour/article/view/2130
https://doi.org/10.20996/1819-6446-2020-02-09

المؤلفون: S. Miklishanskaya V., N. Mazur A., N. Shestakova V., С. Миклишанская В., Н. Мазур А., Н. Шестакова В.

المصدر: Meditsinskiy sovet = Medical Council; № 12 (2017); 75-81 ; Медицинский Совет; № 12 (2017); 75-81 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-12

مصطلحات موضوعية: cardiac fibrosis, collagen, extracellular matrix, extracellular volume, cardiovascular magnetic resonance imaging, фиброз миокарда, коллаген, внеклеточный матрикс, внеклеточный объем, магнитно-резонансная томография

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2013/1996; Глотов М.Н., Мазур Н.А. Диастолическая функция левого желудочка у больных гипертонической болезнью: Обзор. Кардиология. 1994; 1-2:89-93.; Хежева Ф.М., Мазур Н.А. Сывороточные маркеры фиброза у больных артериальной гипертонией. Кардиология. 2006; 3:64-67.; Мазур Н.А. Органные поражения, нарушения метаболизма при артериальной гипертонии и влияние на них гипотензивной терапии. Тер. архив. 1995; 67: 3-5.; Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart Failure With Preserved Ejection Fraction Molecular Pathways of the Aging Myocardium. Circ Res. 2014; 115: 97-107.; Овчинников А.Г., Ожерельева М.Г., Агеев Ф.Т. Фиброз левого желудочка: патогенез, диагностика, лечение. Неотложная кардиология. 2015; №4: 11-26.; Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation. JACC. 2015 66, NO. 8, 943-959.; Ivey M J, Tallquist MD. Defining the Cardiac Fibroblast. Circ J. 2016; 80: 2269–2276.; Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010; 225: 631–637.; Fu J, Srivastava D. Direct Reprogramming of Fibroblasts into Cardiomyocytes for Cardiac Regenerative Medicine. Circ J. 2015; 79: 245– 254.; Baum J, Duffy HS. Fibroblasts and myofibro-blasts: what are we talking about? J Cardiovasc Pharmacol. 2011; 57: 376–379.; Yong KW, Li Y, Huang G et al. Mechanoregulation of cardiac myofibroblast differentiation: implications for cardiac fibrosis and therapy. Am J Physiol Heart Circ Physiol. 2015; 309: H532–H542.; Vasquez C, Benamer N, Morley GE. The Cardiac Fibroblast: Functional and Electrophysiological Considerations in Healthy and Diseased Hearts. J Cardiovasc Pharmacol. 2011; 57(4): 380–388.; Cartledge JE, Kane C, Dias P, et al. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc Res. 2015; 105: 260–70.; Takeda N, Manabe I. Cellular Interplay between cardiomyocytes anda nonmyocytes in cardiac remodeling. Int J Inflam. 2011; 2011: 535241.; Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014; 63: 2335–45.; Wynn Т.А. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214: 199–210.; Lawrie CH. Micro RNAs in Medicine. Wiley-Blackwell. 2013, p.720.; Yilmaz A, Kindermann I, Kindermann M et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences incomplication rate and diagnostic performance. J Circulation. 2010; 122: 900-909.; Moon JC, Messroghli DR, Kellman P et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. Journal of Cardiovascular Magnetic Resonance. 2013, 15:92.; Treibel TA, Zemrak F, Sado DM et al. Extracellular volume quantification in isolated hypertension - changes at the detectable limits? Journal of Cardio vascular Magnetic Resonance. 2015; 17:74-86.; Everett RJ, Stirrat CG, Semple SIR et al. Assessment of myocardial fibrosis with T1 mapping MRI. Clinical Radiology. 2016; 8: 768-778.; Neilan TG, Coelho-Filho OR, Shah RV et al. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. J Am Coll Cardiol Img. 2013; 6: 672–683.; Li Q, Liu X, Wei J. Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent. Biochem Biophys Res Comm. 2014; 452: 497–502.; Wu J, Xia S, Kalionis B et al. The role of oxidative stress and inflammation in cardiovascular aging. BioMed Res Int. 2014; 2014: 615312.; Boon RA, Iekushi K, Lechner S et al. Micro-RNA-34a regulates cardiac ageing and function. Nature. 2013; 495: 107–110.; Schelbert EB, Sabbah HN, Butler J, Gheorghiade M. Employing extracellular volume cardiovascular magnetic resonance measures of myocardial fibrosis to foster novel therapeutics. Circulation: Cardiovascular Imaging 2017;10:e005619.; Travers JG, Kamal FA, Robbins J et al. Cardiac Fibro sis: The Fibroblast Awakens. Circ Res. 2016; 118: 1021–1040.; https://www.med-sovet.pro/jour/article/view/2013

الاتاحة: https://www.med-sovet.pro/jour/article/view/2013
https://doi.org/10.21518/2079-701X-2017-12-75-81

المؤلفون: A. Lomonosova A., N. Mazur A., E. Zolozova A., E. Sayutina V., V. Chigineva V., N. Shestakova V., А. Ломоносова А., Н. Мазур А., Е. Золозова А., Е. Саютина В., В. Чигинева В., Н. Шестакова В.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 8, No 2 (2012); 168-172 ; Рациональная Фармакотерапия в Кардиологии; Vol 8, No 2 (2012); 168-172 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2012-8-2

مصطلحات موضوعية: platelet aggregation, residual reactivity, ischemic heart disease, acetylsalicylic acid, clopidogrel, агрегация тромбоцитов, остаточная реактивность, ишемическая болезнь сердца, ацетилсалициловая кислота, клопидогрел

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/544/565; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996;348(9038):1329–1339.; Hochholzer W., Trenk D., Bestehorn H.P . et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742–1750.; Beigel R., Hod H., Fefer P ., Asher E. et al. Еn of aspirin failure to clinical outcome and to platalet response to aspirin in patients with acute myocardial infarction. Am J Cardiol 2011; 107 (3), 339–342.; Price M. J., Angiolillo D.J , Teirstein P .S. et al. A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. Circulation 2011;124(10):1132–7.; Brar S.S., Ten Berg J., Marcucci R. et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58(19):1945–1954 .; Gurbel P .A., Antonino M.J., Bliden K.P . et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic targetю. Platelets 2008; 19 (8): 595–604.; Bonello L., Tantry U.S., Marcucci R. et al. Consensus and future directions on the definition of high on- treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–933.; Sibbing D., Braun S., Morath T . et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849–56.; Breet N.J., van Werkum J.W., Bouman II.J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754–62.; Sibbing D., Morath T., Braun S. et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151–59.; Geisler T., Zurn Ch., Simonenko R. et al. Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59–66.; Price M.J., Endemann S., Collapudi R.R. et al. Prognostic significance of post-clopidogrel platelet re- activity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992–1000.; Serebruany V., Rao S.Y ., Silva M.A. et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events assessment by different. Eur Heart J 2010; 3: 227–35.; https://www.rpcardio.com/jour/article/view/544

الاتاحة: https://www.rpcardio.com/jour/article/view/544
https://doi.org/10.20996/1819-6446-2012-8-2-12-25